search

Active clinical trials for "Neoplasms"

Results 3171-3180 of 64586

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

SarcomaMelanoma6 more

The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its metastases.

Recruiting43 enrollment criteria

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Colorectal Cancer Metastatic

Open-label multicenter study

Recruiting40 enrollment criteria

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients...

Merkel Cell Carcinoma

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma. Pembrolizumab works by helping patient's immune system to fight cancer. Lutathera works by killing cancer cells. Pembrolizumab is approved by the FDA to treat Merkel cell cancer and has caused some Merkel cell cancers to shrink and/or resolve. Lutathera is FDA-approved to treat some neuroendocrine tumors and has caused some patient's neuroendocrine tumors to shrink and allowed them to live longer, but it is not approved by the FDA to treat Merkel cell cancer. The combination of Lutathera and pembrolizumab to treat Merkel cell cancer is investigational, which means this combination is not approved by the FDA to treat Merkel cell cancer.

Recruiting41 enrollment criteria

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular...

Liver Tumor

To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.

Recruiting25 enrollment criteria

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory...

Nasopharyngeal Carcinoma

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice. Based on previous clinical trials, anti-angiogenic drugs combined with immunotherapy were found to be effective. Therefore, this study intends to preliminarily evaluate which treatment regimen can provide the most benefit to PD-1 inhibitor refractory patients by comparing the efficacy of VEGFR inhibitor or standard chemotherapy combined with PD-1 inhibitor.

Recruiting28 enrollment criteria

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Soft Tissue Sarcoma

The main purpose of this trial is to evaluate the efficacy and safety of TAEST16001 cells in the treatment of advanced soft tissue sarcoma patients with HLA-A*02:01 tissue genotype and positive tumor antigen NY-ESO-1 expression.

Recruiting30 enrollment criteria

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Tenosynovial Giant Cell TumorPigmented Villonodular Synovitis1 more

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: Whether the Pimicotinib(ABSK021) works well in patients with TGCT. Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. Complete the study procedures speficied in the protocol, which is guided by researchers.

Recruiting23 enrollment criteria

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults

Gliomas

To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors

Recruiting47 enrollment criteria

ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Colorectal CancerLiver Metastases2 more

The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and waiting" treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.

Recruiting15 enrollment criteria

Dietary Intervention for NSCLC Patients Treated With ICI

Non Small Cell Lung Cancer

This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.

Recruiting6 enrollment criteria
1...317318319...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs